2022Cell and Gene Therapy InsightsRequires access

Banking on the future of regenerative medicine with cGMP-compliant iPSC lines

Melissa K. Carpenter

Open publisher page 0 citations

Abstract

The ability to generate cell therapies from pluripotent stem cells is changing the way we think about diseases and how to treat them. Regenerative medicines derived from pluripotent stem cells have the potential to treat a large number of diseases, many of which currently lack efficacious therapies, by identifying the deficient or non-functional cell type involved in the disease and generating the corresponding healthy cell type from pluripotent stem cells. However, like other cell and gene therapy products, pluripotent stem cell-based regenerative medicines face development challenges that must be solved before we can deliver on their promise to patients.

About this research paper

What this paper is about

The ability to generate cell therapies from pluripotent stem cells is changing the way we think about diseases and how to treat them. Regenerative medicines derived from pluripotent stem cells have the potential to treat a large number of diseases, many of which currently lack efficacious therapies, by identifying the deficient or non-functional cell type involved in the disease and generating the corresponding healthy cell type from pluripotent stem cells. However, like other cell and gene therapy products, pluripotent stem cell-based regenerative medicines face development challenges that must be solved before we can deliver on their promise to patients.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The ability to generate cell therapies from pluripotent stem cells is changing the way we think about diseases and how to treat them. Regenerative medicines derived from pluripotent stem cells have the potential to treat a large number of diseases, many of which currently lack efficacious therapies, by identifying the deficient or non-functional cell type involved in the disease and generating the corresponding healthy cell type from pluripotent stem cells. However, like other cell and gene therapy products, pluripotent stem cell-based regenerative medicines face development challenges that must be solved before we can deliver on their promise to patients.

Key concepts: Induced pluripotent stem cell, Regenerative medicine, Stem cell, Embryonic stem cell, Cell therapy, Cell type, Neuroscience, Cell

Related papers

Back to paper searchBrowse research topicsOriginal source
Banking on the future of regenerative medicine with cGMP-compliant iPSC lines — Research Paper | ScholarLens